I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Lupin Ltd.

Lupin Chemicals Ltd [LCLs] was promoted by Lupin Laboratories limited The Comp. was incorporated on 31.03.83 as a Private Ltd Comp. & subsequently converted into a Public Ltd Comp. with effect from 23.12.91. The Comp. doesn't have any subsidary.

The Comp. is setting up a project for manufacture of 93 tpa of Rifampicin, an essential anti-tuberculosis, anti-leprotic, life saving drug from a very basic stage of fermentation. It is an import substitute product. To finance the project the Comp. is coming out with a PCD issue aggregating to Rs.45.6 crores.

2002 -Lupin Ltd has successfully introduced AkuriT, a revolutionary simplified therapy as per WHO guidelines for treatment of tuberculosis

-Crisil has upgraded the rating assigned to Lupin non-convertible debentures from D to BB+.

-Lupin Ltd has enhanced its capacity of manufacturing various products at its formulations plants at Aurangabad & Manideep in Madhya Pradesh.

2007

- Lupin receives Final FDA Approval for Trandolapril.

-Lupin Ltd inducted PricewaterHouseCoopers to implement SAP to faultlessly connect its 28 sales depot.

-Lupin Ltd has cut down its debt by Rs.20cr .

2003

-Lupin Ltd has commissioned its facility at Mandideep near Bhopal, Madhya Pradesh for the manufacture of Lisinopril.

-Lupin Ltd announces VRS for its employees in a bid to trim its wage bill.

-Pharmaceutical major Lupin Ltd has divested about 12.55% of its equity holding in the Comp. to CVC International, a private investment arm of US based financial conglomerate Citigroup.

-Lupin is closing down its South African Operations & is setting up two subsidiaries in Hongkong & the US.

-Lupin Ltd has received the appproval of US Food & Drug Administration for cefuroxime axetil 250 mg & 500 mg tablets.

Dr.Kamal K Sharma has been appointed as the Additional Director of company.

-The Comp. has received USFDA approval for cefotaxime sterile vials for injection.

-Secured US FDA nod for generic Claforan marketing

-Lupin receives USFDA approval for Caftriaxone Sterile Vials for injections

-Lupin plans to list shares on NYSE

-Lupin set up new herbal product division

-Lupin submits INDA for psoriasis

2004

-Launches Ezedoc, a specialty drug for cholesterol management segment

-Lupin has appointed Vinod Dhawan as President - Business Development [Latin America, Japan, Australia, & New Zealands]. Mr.Dhawan will be responsible for development of Lupin business strategy for these markets, with focus on, among others, product selection, entry strategy, marketing & sales, & regulatory compliance.

-Lupin Limited has informed that at the EGM of Comp. held on December 05, 2003, the members of Comp. have by means of special resolution determined to delist shares of Company, from the following exchanges : 1s] The Calcutta Stock Exchange Association limited 2s] The Stock Exchange, Ahmedabad, 3s] Jaipur Stock Exchange Ltd., 4s] The Delhi Stock Exchange Association limited The Comp. has initiated action to secure de-listing of equity shares of Company, from the aforesaid exchanges. The Equity shares of Comp. are listed on the NSE & BSE & will continue to be listed & traded on NSE & BSE.

-Enters into an agreement with Baxter Healthcare Corporation, a global medical products Comp. headquartered in the United States, whereby Baxter will exclusively distribute the Company generic version of ceftriaxone sterile vials for injection in the USA

- Floats new division - Lupin Herbal, dedicated to research-based phytomedicines. Unveiled nine herbal products in therapeutic areas, including diabetes, pediatrics, gastro intestinal, pain management & gynaecology

2004

-Delists Shares from Ahmedabad Stock Exchange.

- Lupin Pharmaceuticals, Inc., wholly owned subsidiary of Comp. has entered into an agreement with Allergan, Inc. in the United States to promote Zymar [gatifloxacin opthalmic solutions] 0.3% in the pediatric specialty area.

-Lupin Ltd has launched its anti-infective product Suprax [cefixime Oral Suspensions] in the US market.

-Shares of Lupin Ltd delisted from the Delhi Stock Exchange

- Shares of Lupin Ltd delisted from Jaipur Stock Exchange

- Ind Swift Ltd ties up with Lupin Ltd for a Co-marketing pact to launch Nitazoxanide, an anti-diarrhoeal / anti-helmintic drug for first time in India under the brand name Netazox & Nizonide respectively.

2005

-Lupin launches Ceftriaxone vials in the US market

-Lupin enters into co-operation agreement with Kyowa for Japanese market.

-Lupin receives USFDA approvals for Cephalexin Oral Suspension

-Lupin has entered into an agreement with GSK Philippines to manufacture & supply the 4 and 2 Drug FDCs for marketing in Philippines.

-Lupin receives approval for conducting phase II clinical trials of Investigation New Drug candidate LLL-3348 [Desoriss] from the Drug Controller General of India.

2006

-Lupin joins hands with ItalFarmaco to launch Lupenox in India

-Lupin receives DCGI approval to conduct Phase II clinical Trials for Psoriasis NCE

2007

- Lupin Receives US FDA Approval for Simvastatin Tablets

- Lupin gets MHRA Approval for Lisinopril in UK

- Lupin Ltd has announced that it has received Euro 20 million from Laboratoires Servier of France for sale of additional patent rights for Perindopril.

2008

-Lupin Limited has appointed Mr. R.V. Satam as Secretary and Compliance Officer of Comp. w.e.f. May 01, 2008.